Genome & Company (KOSDAQ:314130)

Market Cap	266.01B +236.9%
Revenue (ttm)	24.02B -19.5%
Net Income	-5.71B
EPS	-177.11
Shares Out	44.71M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,046,932
Open	4,845.00
Previous Close	4,845.00
Day's Range	4,715.00 - 6,090.00
52-Week Range	2,440.00 - 10,180.00
Beta	0.35
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 14, 2026

About Genome & Company

Genome & Company, a clinical stage biotechnology company, researches and develops novel-targeted immuno-oncology therapeutics in the field of immuno-oncology, skin diseases, and autism in South Korea, Asia, Europe, South America, North America, and internationally. Its lead product candidate is GEN-001, an oral microbiome therapeutic candidate developed to have immune modulating activities. The company also develops GEN-501 targeting the non-responders of Dupilumab drugs with atopic skin diseases; and GENA-104 for the treatment of solid tumors,...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2015
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 314130

Financial Performance

In 2025, Genome & Company's revenue was 24.59 billion, a decrease of -11.38% compared to the previous year's 27.74 billion. Losses were -6.43 billion, -68.04% less than in 2024.